Oxford Ventures (fka OXFV)

[Minddoc7]

*** NEWS ***
http://biz.yahoo.com/prnews/060405/daw033.html?.v=50

Oxford Ventures Announces Completion of Merger With ULURU
Wednesday April 5, 8:00 am ET
- Name Change to ULURU Inc.
- Symbol Change on the OTC Bulletin Board: ULUR
- Implementation of Reverse Stock Split


DALLAS, April 5 /PRNewswire-FirstCall/ -- Oxford Ventures, Inc. (OTC Bulletin Board: OXFV - News; "OXFORD") today announced that its merger with ULURU, Inc. ("ULURU") has been completed. Under the terms of the merger agreement, ULURU has been merged into a subsidiary of Oxford, with Oxford being the surviving legal entity. Oxford has acquired all of the outstanding shares of ULURU in exchange for unregistered common stock of Oxford.
Oxford's name has been changed to ULURU Inc. and the new company headquarters are located at 4452 Beltway Drive, Addison, Texas, 75001.

Mr. Kerry P. Gray will be President and C.E.O. of ULURU. Additionally, Mr. Gray will serve on the Board of Directors along with:


Mr. William W. Crouse, Chairman
Mr. Jeffery B. Davis
Dr. David E. Reese

Effective April 5, 2006 the trading symbol on the OTC Bulletin Board will change from OXFV to ULUR. Additionally, the company has implemented a 1-for-400 reverse stock split. The reverse stock split will take effect and the shares will begin trading on a post-split basis at the opening of business on Wednesday, April 5, 2006.

With the completion of the merger and the reverse stock split the company will have approximately 13 million common shares outstanding. Shareholders will be notified by Continental Stock Transfer & Trust Company, ULURU's stock transfer agent, regarding the process for receiving new share certificates.

ULURU's business plan is to establish a market leadership position in the development of wound management, plastic surgery and oral care products utilizing innovative drug delivery solutions to improve clinical outcomes for patients and provide an economic benefit to healthcare providers. The company intends to establish a sales and marketing organization to market our product developments to the wound management and plastic surgery markets and to form strategic partnerships to market our range of oral products and other product developments that require a large sales organization. Acquiring and licensing products for wound management and plastic surgery is an integral component of our strategy of rapidly building a sales and marketing organization.

Commenting on the recent developments, Kerry P. Gray, President and C.E.O. of ULURU, stated, "With the completion of the merger and the appointment of a highly qualified Board of Directors, I look forward with excitement to building a leading company in the wound management, plastic surgery and oral care markets. We are very pleased with our progress in developing products from our technology platforms. Over the upcoming 12 months we expect three additional products to be marketed."

Mr. Gray continued, "The reverse split brings the number of shares outstanding and the share price more in line with companies of our size and stage of development. This is the first step to achieve our ultimate objective of applying for a listing on NASDAQ or an exchange."

ULURU Inc. is an emerging specialty pharmaceutical company focused on the development of a portfolio of wound management, plastic surgery and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative transmucosal delivery system and Hydrogel Nanoparticle Aggregate technology.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks, and uncertainties, including but not limited to statements made relating to the establishment of a sales and marketing organization, the marketing of three additional products and the achievement of a listing on NASDAQ or an exchange. These statements are subject to numerous risks, including but not limited to the risks detailed in the Company's Annual Report on Form 10-K, for the year ended December 31, 2004, Quarterly Report on Form 10-Q for the quarter ended September 30, 2005 and other reports filed by us with the Securities and Exchange Commission.


Contact Company
Kerry P. Gray
President and CEO

Terry K. Wallberg
Chief Financial Officer
[phone]